Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus

Seminars in Cancer Biology

Volumn 18, Issue 6, 2008, Pages 409-415

  Delecluse, Henri Jacques ^a   Feederle, Regina ^a   Behrends, Uta ^b   Mautner, Josef ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Epstein Barr virus; Genetic analysis; Immune response; T cells

Indexed keywords

ANTIGEN; VIRUS ANTIGEN; VIRUS DNA; VIRUS PROTEIN;

ANTIGEN RECOGNITION; B LYMPHOCYTE; BACTERIAL ARTIFICIAL CHROMOSOME; BACTERIAL CELL; CELL CLONE; CELL DIVISION; CELL SPECIFICITY; CELL THERAPY; DNA PACKAGING; EPSTEIN BARR VIRUS; ESCHERICHIA COLI; GENE VECTOR; GENETIC ANALYSIS; GENETIC IDENTIFICATION; HELPER CELL; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOBLASTOID CELL LINE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PHENOTYPE; PLASMID; PROTEIN DOMAIN; REVIEW; T LYMPHOCYTE; VIRION; VIRUS GENOME; VIRUS LIKE AGENT; VIRUS RECOMBINANT;

ANTIGENS, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; GENETIC VECTORS; GENOME, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; PLASMIDS; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL VACCINES;

EID: 56949103578     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2008.09.001     Document Type: Review

References (50)

1. Kieff E., and Rickinson A.B. Epstein-Barr virus and its replication. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., et al. (Eds). Fields virology. 5th edition (2007), Lippincott Williams & Wilkins, Philadelphia 655-700
2. Delecluse H.J., Pich D., Hilsendegen T., Baum C., and Hammerschmidt W. A first-generation packaging cell line for Epstein-Barr virus-derived vectors. Proc Natl Acad Sci USA 96 (1999) 5188-5193
3. Mackey D., and Sugden B. Applications of oriP plasmids and their mode of replication. Methods Enzymol 306 (1999) 308-328
4. Hammerschmidt W. Herpesvirus vectors come of age. Curr Opin Mol Ther 2 (2000) 532-539
5. Kempkes B., Zimber-Strobl U., Eissner G., Pawlita M., Falk M., Hammerschmidt W., et al. Epstein-Barr virus nuclear antigen 2 (EBNA2)-oestrogen receptor fusion proteins complement the EBNA2-deficient Epstein-Barr virus strain P3HR1 in transformation of primary B cells but suppress growth of human B cell lymphoma lines. J Gen Virol 77 (1996) 227-237
6. Bloss T.A., and Sugden B. Optimal lengths for DNAs encapsidated by Epstein-Barr virus. J Virol 68 (1994) 8217-8222
7. Kempkes B., Pich D., Zeidler R., Sugden B., and Hammerschmidt W. Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA. J Virol 69 (1995) 231-238
8. O'Connor M., Peifer M., and Bender W. Construction of large DNA segments in Escherichia coli. Science 244 (1989) 1307-1312
9. Smiley J.R. Construction in vitro and rescue of a thymidine kinase-deficient deletion mutation of herpes simplex virus. Nature 285 (1980) 333-335
10. Mocarski E.S., Post L.E., and Roizman B. Molecular engineering of the herpes simplex virus genome: insertion of a second L-S junction into the genome causes additional genome inversions. Cell 22 (1980) 243-255
11. Post L.E., and Roizman B. A generalized technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential for growth. Cell 25 (1981) 227-232
12. Hammerschmidt W., and Sugden B. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340 (1989) 393-397
13. Cohen J.I., Wang F., Mannick J., and Kieff E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci USA 86 (1989) 9558-9562
14. Tomkinson B., Robertson E., Yalamanchili R., Longnecker R., and Kieff E. Epstein-Barr virus recombinants from overlapping cosmid fragments. J Virol 67 (1993) 7298-7306
15. Izumi K.M. Identification of EBV transforming genes by recombinant EBV technology. Semin Cancer Biol 11 (2001) 407-414
16. Neuhierl B., and Delecluse H.J. Molecular genetics of DNA viruses: recombinant virus technology. Methods Mol Biol 292 (2005) 353-370
17. Rickinson A.B., and Kieff E. Epstein-Barr virus. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., et al. (Eds). Fields virology. 5th edition (2007), Lippincott Williams & Wilkins, Philadelphia 2655-2700
18. Moosmann A., Khan N., Cobbold M., Zentz C., Delecluse H.J., Hollweck G., et al. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood 100 (2002) 1755-1764
19. + T cells by mini-EBV-transformed B cell lines. Eur J Immunol 35 (2005) 2110-2121
20. Milosevic S., Behrends U., Adhikary D., and Mautner J. Identification of major histocompatibility complex class II-restricted antigens and epitopes of the Epstein-Barr virus by a novel bacterial expression cloning approach. J Virol 80 (2006) 10357-10364
21. Adhikary D., Behrends U., Moosmann A., Witter K., Bornkamm G.W., and Mautner J. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 203 (2006) 995-1006
22. + T cell preparations for therapy. PLoS ONE 2 (2007) e583
23. Feederle R., Kost M., Baumann M., Janz A., Drouet E., Hammerschmidt W., et al. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 19 (2000) 3080-3089
24. Landais E., Saulquin X., Scotet E., Trautmann L., Peyrat M.A., Yates J.L., et al. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood 103 (2004) 1408-1416
25. Landais E., Saulquin X., Bonneville M., and Houssaint E. Long-term MHC class II presentation of the EBV lytic protein BHRF1 by EBV latently infected B cells following capture of BHRF1 antigen. J Immunol 175 (2005) 7939-7946
26. Feederle R., Neuhierl B., Baldwin G., Bannert H., Hub B., Mautner J., et al. Epstein-Barr virus BNRF1 protein allows efficient transfer from the endosomal compartment to the nucleus of primary B lymphocytes. J Virol 80 (2006) 9435-9443
27. + T cells by using virus-like particles. J Virol 82 (2008) 3903-3911
28. Lee M.A., Diamond M.E., and Yates J.L. Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus. J Virol 73 (1999) 2974-2982
29. Humme S., Reisbach G., Feederle R., Delecluse H.J., Bousset K., Hammerschmidt W., et al. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc Natl Acad Sci USA 100 (2003) 10989-10994
30. + T helper cells. Eur J Immunol 34 (2004) 2500-2509
31. Lee S.P., Brooks J.M., Al-Jarrah H., Thomas W.A., Haigh T.A., Taylor G.S., et al. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J Exp Med 199 (2004) 1409-1420
32. + T cell epitopes. J Exp Med 204 (2007) 525-532
33. + immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med 201 (2005) 349-360
34. Feederle R., Shannon-Lowe C., Baldwin G., and Delecluse H.J. Defective infectious particles and rare packaged genomes produced by cells carrying terminal-repeat-negative Epstein-Barr virus. J Virol 79 (2005) 7641-7647
35. Hutt-Fletcher L.M. Epstein-Barr virus entry. J Virol 81 (2007) 7825-7832
36. Sokal E.M., Hoppenbrouwers K., Vandermeulen C., Moutschen M., Leonard P., Moreels A., et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 196 (2007) 1749-1753
37. Moutschen M., Leonard P., Sokal E.M., Smets F., Haumont M., Mazzu P., et al. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 25 (2007) 4697-4705
38. Davis M.M. Successes and remaining challenges after 10 years of varicella vaccination in the USA. Expert Rev Vaccines 5 (2006) 295-302
39. Heininger U., and Seward J.F. Varicella. Lancet 368 (2006) 1365-1376
40. Wilson J.B., Bell J.L., and Levine A.J. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 15 (1996) 3117-3126
41. Kennedy G., Komano J., and Sugden B. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci USA 100 (2003) 14269-14274
42. Kang M.S., Soni V., Bronson R., and Kieff E. Epstein-Barr virus nuclear antigen 1 does not cause lymphoma in C57BL/6J mice. J Virol 82 (2008) 4180-4183
43. Kang M.S., Lu H., Yasui T., Sharpe A., Warren H., Cahir-McFarland E., et al. Epstein-Barr virus nuclear antigen 1 does not induce lymphoma in transgenic FVB mice. Proc Natl Acad Sci USA 102 (2005) 820-825
44. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 6 (2007) 381-390
45. Ramqvist T., Andreasson K., and Dalianis T. Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin Biol Ther 7 (2007) 997-1007
46. Dargan D.J., Patel A.H., and Subak-Sharpe J.H. PREPs: herpes simplex virus type 1-specific particles produced by infected cells when viral DNA replication is blocked. J Virol 69 (1995) 4924-4932
47. Mocarski E.S., Shenk T., and Pass R.F. Cytomegaloviruses. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., et al. (Eds). Fields virology. 5th edition (2007), Lippincott Williams & Wilkins, Philadelphia 2701-2772
48. Ressing M.E., van Leeuwen D., Verreck F.A., Keating S., Gomez R., Franken K.L., et al. Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. J Virol 79 (2005) 841-852
49. Rowe M., Glaunsinger B., van Leeuwen D., Zuo J., Sweetman D., Ganem D., et al. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci USA 104 (2007) 3366-3371
50. + T cells through an additional host shutoff function. J Virol 82 (2008) 2385-2393